Atty. Docket No: 023231-00033

## In the Specification:

Please amend the specification as shown:

Please amend the paragraph found on page 20, line 20 to page 21, line 8, to read as follows:

## Example 1: Construction of Plasmids

A 1,061 bp fragment containing the wheat puroindoline b promoter and signal peptide was amplified from genomic DNA of *Triticum aesvestium*, cv. Bobwhite by *Pfu* DNA polymerase using reverse primer: 5'GGGAATATTGTACCAGCCGCCAACTTCTGA-3' (SEQ ID NO: 1) and forward primer: 5'-CCGCTGCAGCTCCAACATCTTATCGCAACATCC-3' (SEQ ID NO: 2), designed

from the sequences of Genbank accession number AJ000548. The reverse primer introduces a silent mutation into the signal peptide, creating a *Bcl* I site for in-frame fusion of a recombinant gene. The fragment was cloned into the pCR2.1 vector (Invitrogen, Carlsbad, CA). After confirmation by sequencing analysis, the fragment was cut by *SphI*, and cloned into the *Nael/SphI* site of API241 (Hwang et al., "Analysis of the rice endosperm-specific globulin promoter in transformed rice cells", (2002) Plant Cell Report 20: 842-847). This backbone contains a 1.8 kb stuffer fragment, the nopaline synthase terminator (NOS), and an ampicillin resistance selectable marker gene. This intermediate construct was designated API302 (Figure 1, top). Next, API302 was cut with *Bcl I*, blunted by Mung Bean Nuclease, and then digested with *XhoI* to remove the stuffer fragment. A human lysozyme gene (GenBank accession No. X63990), codonoptimized with rice preferred codons (Operon Technologies, Alameda, CA), was inserted into the vector in place of the stuffer fragment. The resulting construct was designated as pAPI308 (Figure 1, middle).

Atty. Docket No: 023231-00033

Please amend Table 2 found on page 24, to read as follows:

Table 2. N-terminal sequences comparison of rLys and native human lysozyme

Native human lysozyme	KVFERCELART (SEQ ID NO: 8)
Rice recombinant human lysozyme	KVFER( )ELART (SEQ ID NO: 9)

Note: Cysteine can not be detected in amino acid sequencing reaction

Please amend the table found on pages 28 to 30 to read as follows: Brief Description of the Codon Optimized Nucleic Acid Sequences

Description	SEQ ID NO
Pfu DNA polymerase reverse primer	1
5'-GGGAATATTGTACCAGCCGCCAACTTCTGA-3'	
Pfu DNA polymerase forward primer	2
5'-CCGCTGCAGCTCCAACATCTTATCGCAACATCC-3'	
Codon optimized lysozyme coding sequence:	3
AAAGTCTTCGAGCGGTGCGAGCTGGCCCGCACGCTCAAGCGGCTCGGCAT	
GGACGGCTACCGGGGCATCAGCCCCCAACTACAACCCCGGCGACCA	
GGGAGTCGGGCTACAACACCCGCGCAACCAACTACAACGCCGGCGACCG CTCCACCGACTACGGCATCTTCCAGATCAACTCCCGCTACTGGTGCAACGA	
CGGCAAGACGCCCGGGGCCGTCAACGCCTGCCACCTCTCCTGCTCGGCC	
CTGCTGCAAGACAACATCGCCGACGCCGTCGCGTGCGCGAAGCGCGTCGT	
CCGCGACCGCAGGCATCCGGGCCTGGGTGGCCTGGCGCAACCGCTGC	
CAGAACCGGGACGTGCGCCAGTACGTCCAGGGCTGCGGCGTCTGA	
Amino acid sequence based on codon optimized lysozyme coding	<u>10</u>
sequence:	
KVFERCELARTLKRLGMDGYRGISLANWMCLAKWESGYNTRATNYNAGDRST	
DYGIFQINSRYWCNDGKTPGAVNACHLSCSALLQDNIADAVACAKRVVRDPQG IRAWVAWRNRCQNRDVRQYVQGCGV	
	4
Gt1 promoter sequence CATGAGTAATGTGAGCATTATGGGACCACGAAATAAAAAGAACATTTTGA	
TGAGTCGTGTATCCTCGATGAGCCTCAAAAGTTCTCTCACCCCGGATAAGA	

AACCCTTAAGCAATGTGCAAAGTTTGCATTCTCCACTGACATAATGCAAAAT	
AAGATATCATCGATGACATAGCAACTCATGCATCATATCATGCCTCTCTCAA	
CCTATTCATTCCTACTCATCTACATAAGTATCTTCAGCTAAATGTTAGAACAT	
AAACCCATAAGTCACGTTTGATGAGTATTAGGCGTGACACATGACAAATCAC	
AGACTCAAGCAAGATAAAGCAAAATGATGTGTACATAAAACTCCAGAGCTAT	
ATGTCATATTGCAAAAAGAGGGAGAGCTTATAAGACAAGGCATGACTCACAAA	
AATTCACTTGCCTTTCGTGTCAAAAAGAGGGGGCTTTACATTATCCATGTC	
ATATTGCAAAAGAAGAGAGAAGAACAACACAATGCTGCGTCAATTATACA	
TATCTGTATGTCCATCATTATTCATCCACCTTTCGTGTACCACACTTCATATA	
TCATAAGAGTCACTTCACGTCTGGACATTAACAAACTCTATCTTAACATTTAG	
ATGCAAGAGCCTTTATCTCACTATAAATGCACGATGATTTCTCATTGTTTCTC	
ACAAAAAGCGGCCGCTTCATTAGTCCTACAACAAC	
Gt1 signal sequence	5
ATGGCATCCATAAATCGCCCCATAGTTTTCTTCACAGTTTGCTTGTTCCTCTT	
GTGCGATGGCTCCCTAGCC	6
Purindoline promoter sequence	
AAGCTTGCATGCCTGCAGAATGCCAGAATAAGAGGGGGAGAAGCTAGTCC	
TATCAAAGACTACGCTTCCAGTAACCTCCGTCTCGCAGTAGTAGAAGAGAA	
TAGCAGATAAGTATCAACACATAGCATAACCCACCTGGCGATCCTCTCTTG	
TCACCCTGTGAGAGAGCGAACACCGGGTTGTATCTGGAAGTTATCTGGGTG	
TGCTTTATTAAGTCGGCTGGTACATCATCCTCCCATAGGAGGCCTTTGCATC	
TGGGCGTGTGTGGCCTATTTTCATTTCACCCCAGTTATTCCATCGAACTAAG	
TAGCAACATGTAAGGAGTCAGTTTTCGAGATACCACACACA	
AACGAAACTAATGAGAAATAAAAAGGTGCATCACTCATTTTCGACCAAATTA	
ATTATGTCTTGGTATTAGAGTTTTCTCTCTCTGTCCTGATAAACCCAAACGG	
AGGAGTAAAGATTATCTATCTCAACATCACATGATTCTAAATACAAAACAGAA	
AACCACGGCTAGAAGAGGACGACATCTAGAGGCATTGCTTTTCATGTACTA	
ATACCTTGTTAAACACATTCTCTAACAAATTGGTTTGGATCCTTCTTCAACAA	
TTTCCACACACTACAAGGCCAGTTCACAAAAGCTTAAAGCGTGAGCATTGG	
TACAAAACTAGTTGTGGTCTATCTTGAGAAAAGGGAACACTTAGTACACGAA	
ACGTCACCTGTCTCAACAACTTGCACCATTTCTGTTGGCTCGCAAAGTAACT	
TTATTTAGTATACCAACTTAATTTGTGAGCATTAGCCAAAGCAACACACAATG	
GTAGGCAAAAACCATGTCACTAAGCAATAAATAAAGGGGAGCCTCAACCCA	,
TCTATTCATCTCCACCACCACCAAAACAACATTGAAAAC	7
Purindoline signal sequence	
ATGAAGACCTTATTCCTCCTAGCTCTCCTTGCTCTTGTAGCGAGCACAACCT	
TCGCGCAATACTCAGAAGCTGGCGGCTGGTACAAT	

Please insert the text of the attached paper copy of the Sequence Listing as pages 31-34.